Related Experiment Video

Updated: Jun 27, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Interactions between rs5498 polymorphism in the ICAM1 gene and traditional risk factors influence susceptibility to

Beata Sarecka-Hujar1, Iwona Zak, Jolanta Krauze

  • 1Department of Biochemistry and Medical Genetics, Medical University of Silesia, Medykow Str 18, 40-752 Katowice, Poland. beatasarecka@poczta.onet.pl

Clinical and Experimental Medicine
|December 3, 2008
PubMed

Insights

The Intercellular Adhesion Molecule-1 (ICAM1) rs5498 polymorphism did not directly associate with coronary artery disease (CAD). However, the G allele showed a synergistic effect with smoking and high triacylglycerols, significantly increasing CAD risk.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Epidemiology

Background:

  • Coronary artery disease (CAD) results from genetic and environmental factors.
  • Adhesion molecules, like Intercellular Adhesion Molecule-1 (ICAM-1), indicate endothelial dysfunction and contribute to atherosclerosis.
  • ICAM-1 facilitates leukocyte-endothelial cell interactions, promoting the atherosclerotic process.

Purpose of the Study:

  • To investigate the association between the ICAM1 rs5498 polymorphism and CAD.
  • To determine if interactions between the ICAM1 rs5498 polymorphism and traditional risk factors influence CAD risk.

Main Methods:

  • Study included 191 CAD patients and 203 controls.
  • ICAM1 rs5498 polymorphism genotyped using PCR-RFLP.
  • Statistical analysis performed using STATISTICA 7.1 and EpiInfo 6 software.

Main Results:

  • No significant differences in ICAM1 rs5498 genotype or allele distribution between CAD cases and controls.
  • A tendency for higher G allele carrier prevalence in patients (68%) vs. controls (64%).
  • Significant synergistic effect observed between G allele carrier status and smoking (SIM=2.09), and between G allele carrier status and elevated triacylglycerols (SIM=1.28) on CAD risk.

Conclusions:

  • The ICAM1 rs5498 polymorphism itself is not a significant risk factor for CAD.
  • A synergistic interaction exists between the ICAM1 rs5498 G allele carrier status and smoking, significantly elevating CAD risk.
  • Synergistic effect also noted between G allele carrier status and high triacylglycerols, contributing to increased CAD risk.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...